Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
354 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Currently Recruiting (2)
  • Closed (21)

Medical Condition

  • Show all (90)
  • Autoimmune Disorders (1)
  • Blood Disorders (4)
  • Bone & Muscle (1)
  • (-) Cancer (23)
    • Breast Cancer (1)
    • Gynecologic Cancer (2)
    • Head and Neck Cancer (1)
    • Leukemia (3)
    • Liver Cancer (1)
    • Lung Cancer (2)
    • Lymphoma (1)
    • Multiple Myeloma (2)
    • Pancreatic Cancer (1)
    • Prostate Cancer (1)
    • Solid Tumors (2)
    • Uveal Melanoma (2)
  • COVID-19 (Coronavirus) (4)
  • Diabetes (2)
  • Endocrine & Metabolic Disease (3)
  • Healthy Volunteers (10)
  • Heart Disease (17)
  • Kidney Disease (1)
  • Liver Disease (1)
  • Lung Disease (2)
  • Neurological Disorders (3)
  • Nutrition (1)
  • Obesity (2)
  • Obstetrics & Gynecology (3)
  • Pediatrics (7)
  • Surgery (2)
  • Transplant (3)
Displaying 1 - 23 of 23

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML

Condition: Cancer / Leukemia
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This is a phase 1 study for participants with relapsed/refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) diagnosis. This study will observe the safety, side effects, and best dose of Imetelstat as an investigational drug, or drug that is not approved by the Food and Drug Administration (FDA…
Read More

The Cancer of the Pancreas Screening-5 Study (CAPS5 Study)

Condition: Cancer / Pancreatic Cancer
Investigator: Fay Kastrinos, MD
Status: Currently Recruiting
Pancreatic cancer is a deadly disease and the best hope for improving the chances of survival is to find it early. Some patients, called "high risk", have an inherited predisposition to pancreatic cancer. Certain medical centers have started programs where "high risk patients" undergo testing,…
Read More

Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)

Condition: Cancer / Multiple Myeloma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to determine if the investigational therapy called bb2121 is effective in treating multiple myeloma. bb2121 is a type of therapy known as chimeric antigen receptor (CAR) T-cell therapy. T cells are a kind of white blood cell which form part of your body's immune system. Your T cells will be…
Read More

A Study of Atezolizumab Plus Bevacizumab Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence

Condition: Cancer / Liver Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to compare the effects, good or bad, of atezolizumab plus bevacizumab versus observation (not receiving any treatment) on patients with completely resected (surgically removed) or ablated (removed using heat) hepatocellular carcinoma (the most common type of liver cancer) who are at high risk for…
Read More

Study For Patients Of Multiple Myeloma Therapy Prior To Stem Cell Transplant With Or Without Lenalidomide/Dexamethasone

Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
This research study is being done to compare the combination of lenalidomide and dexamethasone followed by autologous peripheral blood stem cell transplant (PBSCT) and lenalidomide and dexamethasone without PBSCT in subjects with untreated multiple myeloma. This comparison will include how many subjects respond to each study…
Read More

Study of JNJ-78278343 in Patients with Advanced Prostate Cancer

Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
You are being invited to take part in a research study that includes studying JNJ-78278343 in subjects with prostate cancer. This is an investigational drug which means that this is a new approach for the treatment of people who have prostate cancer. The main purpose of this study is to find a safe dose of JNJ-78278343 that can be used in the treatment of…
Read More

Study of Durvalumab with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1)

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
This study is aimed at finding patients who have small amounts of cancer DNA in their blood (called circulating tumor DNA or ctDNA) after surgery. This may indicate that you have minimal residual disease (MRD), meaning that even after surgery, there are still some remaining cancer cells releasing cancer DNA into your…
Read More

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Condition: Cancer / Head and Neck Cancer
Investigator: Matthen Mathew, MD
Status: Closed
There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this…
Read More

Study of VX15/2508 in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors

Condition: Cancer / Solid Tumors
Investigator: Luca Szalontay, MD
Status: Closed
This is a Phase 1/2 multicenter study of VX15/2503 in pediatric patients and young adults with solid tumors which have come back or have not responded to standard therapy. The study treatment is considered experimental because VX15/2503 is not approved by the United States (US) Food and drug Administration (FDA) for treating pediatric patients and young…
Read More

TrACER: Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) for Patients Receiving Chemotherapy

Condition: Cancer / Breast Cancer
Investigator: Dawn Hershman, MD
Status: Closed
This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia. Patients receiving chemotherapy may develop febrile neutropenia. Febrile neutropenia is a condition that involves fever and a low…
Read More

Study of NDI-101150 Alone or in Combination with Pembrolizumab in Patients with Solid Tumors

Condition: Cancer
Investigator: Ryan Moy, MD
Status: Closed
The purpose of this study is to find out if a new investigational drug NDI-101150 is safe when given alone and in combination with pembrolizumab, and to look at the pharmacokinetics (PK, to measure how your body takes up, breaks down, and clears NDI-101150) and the antitumor activity (to measure how NDI-101150 works in your tumors). Investigational means…
Read More

Study of SL-172154 in Combination with PLD or MIRV in Patients with Ovarian Cancer

Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Closed
The purpose of this research study is to test the safety and determine the highest tolerable dose of SL-172154 (study drug) that can be given with Pegylated Liposomal Doxorubicin (PLD) or Mirvetuximab Soravtansine (MIRV). Another purpose of this study is to understand if SL-127154 and PLD or MIRV is effective in managing…
Read More

Study of STK-009 in Combination with SYNCAR-001 in Patients with Lymphoma or Leukemia

Condition: Cancer / Leukemia
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to find the highest dose of STK-009 that is safe in combination with a dose of SYNCAR-001 and to learn what side effects are experienced in people with certain lymphomas or leukemias. This study will also evaluate how much SYNCAR-001 and STK-009 is in your blood at…
Read More

Study of STK-009 in Combination with SYNCAR-001 in Patients with Lymphoma or Leukemia

Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to find the highest dose of STK-009 that is safe in combination with a dose of SYNCAR-001 and to learn what side effects are experienced in people with certain lymphomas or leukemias. This study will also evaluate how much SYNCAR-001 and STK-009 is in your blood at…
Read More

LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkins Lymphoma

Condition: Cancer
Investigator: Nicole Lamanna, MD
Status: Closed
This research study is being done to test the safety of an investigational treatment called LOXO-305. LOXO-305 is an investigational drug that may treat certain cancers like leukemias and lymphomas, including the one you have been diagnosed with. These cancers are dependent on or addicted to a protein made by the cancers called BTK. LOXO-305 is a BTK…
Read More

A study for patients acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm using study drug SL-401

Condition: Cancer / Leukemia
Investigator: Todd Rosenblat, MD
Status: Closed
The goal of this research study is to find the safest highest dose of SL-401 that can be given to patients with AML or BPDCN. This study will also look at how SL-401 stops or slows leukemia or BPDCN growth and how SL-401 enters and leaves the body. This study will also look at certain proteins in the …
Read More

A study for patients with advanced cancers using oral study drug MGCD265

Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The goal of this clinical research study is to find the highest safe dose of the drug MGCD265 thatcan be given to patients with advanced cancer. The safety of this drug, and the effect that it hason your disease and your body will also be studied.MGCD265 is a drug that works by blocking proteins that are important for cancer…
Read More

A Dose Escalation Trial of AEB102 in Patients with Advanced Solid Tumors

Condition: Cancer / Solid Tumors
Investigator: Richard Carvajal, MD
Status: Closed
This is a Phase 1 multiple dose, dose escalation trial in patients with advanced solid tumors who have failed or cannot tolerate standard therapies. Your study doctor has determined that you have an advanced cancer (solid tumor). You are invited to take part in this research study. This study has two parts. In Part 1, the dose escalation portion, the…
Read More

A study for patients with uveal melanoma using study drug AEB071

Condition: Cancer / Uveal Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is evaluate the benefits and safety of using the combination of drugs, AEB071 and BYL719 to treat patients with an advanced form of uveal melanoma. The study will have two parts. The first part twill test different dose levels of each drug.Once the highest safe dose level is found, another group of…
Read More

A study for patients with advanced cancers using study drug PEN-221

Condition: Cancer
Investigator: Antonio Fojo, MD, PhD
Status: Closed
This study is for patients with advanced cancers such as gastroenteropancreatic or lung or thymus or other neuroendocrine tumors or small cell lung cancer or large cell neuroendocrine carcinoma of the lung. This research study tests whether an experimental drug called PEN-221 may help people with before mentioned cancers. It is thought that PEN-221 might…
Read More

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
This research study is testing two potential new drugs called AB928 and AB122. AB928 is an investigational drug that has been shown in animal studies to improve the functioning of the immune system, without causing any immune effects on its own. This research study will help us understand whether AB928, the study drug, can be safely given in combination…
Read More

Study of LXS196 in Patients with Uveal Melanoma

Condition: Cancer / Uveal Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
You are invited to join voluntarily in a clinical research study to find out if the drug LXS196 alone or in combination with HDM201 is safe and has beneficial effects in people who have metastatic uveal melanoma. The purpose of this study is to determine the highest dose of LXS196 that can be given safely without unacceptable…
Read More

Study of Upifitamab Rilsodotin (XMT-1536) in Patients with Recurrent Ovarian Cancer

Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
XMT-1536 (upifitamab rilsodotin) is a targeted therapy, which means that it is directed specifically at a tumor. It is a type of antibody-drug conjugate; this means it has 2 parts that are joined together into one drug. The first part is an antibody that binds to NaPi2b (sodium-dependent phosphate transporter), a protein on the surface of the cells of your…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science